A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

Radiation Oncology Program

New Therapy Offered for Patients with Recurrent Glioblastoma

Non-invasive treatment uses alternating electrical fields to disrupt tumor growth


Ask the Expert

Dr. Minesh Mehta’s Bio Image

Get answers to your TTF questions.

Dr. Minesh Mehta’s Bio | Q&A Archive

Note: This is for informational purposes only. Doctors cannot provide a diagnosis or individual treatment advice via e-mail. Please consult your physician about your specific health care concerns.

Related Content


Experts in the Department of Radiation Oncology, together with a multidisciplinary team of oncologists and neurosurgeons at the University of Maryland Marlene and Stewart Greenebaum Cancer Center, have begun offering a new treatment for patients with recurrent glioblastoma, a deadly type of brain tumor that is resistant to chemotherapy and radiation.

The treatment, known as Tumor Treating Fields (TTF), is delivered to the patient via a device that fits over the scalp like a bathing cap. It works by emitting alternating electrical fields to the tumor that disrupt the division of cancer cells and stop tumor growth. The device was approved by the Food and Drug Administration (FDA) for the treatment of recurrent glioblastoma in 2011.

“We are very limited in what we have been able to offer these patients once they have had chemotherapy and radiation and their tumor progresses,” says Minesh Mehta, M.B.Ch.B., professor of radiation oncology, medical director of the Maryland Proton Treatment Center and associate director of clinical research in the Department of Radiation Oncology. “This new therapy has shown survival in this patient population that is comparable to that achieved with chemotherapy, but with fewer side effects.”

The device will be further studied in a randomized trial being developed by a national co-operative group brain tumor committee led by Dr. Mehta, who is also developing a trial to test whether the device can be combined with stereotactic radiosurgery to delay the use of whole brain radiotherapy in patients with brain metastases.

The TTF device is worn continuously for several hours every day, and patients return for check-ups at one-to-two-month intervals.

“We are encouraged by the results we are seeing in our patients with this very challenging disease,” says William Regine, M.D., professor and Isadore & Fannie Schneider Foxman Endowed Chair in Radiation Oncology at the University of Maryland School of Medicine.

For more information about this treatment option, please call the Department of Radiation Oncology at 410-328-6080. For more information or to make an appointment for a consultation with our Brain Tumor Center team, please call 1-800-888-8823 or 410-328-7904.

This page was last updated on: January 15, 2013.

For More Information